within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A04A_AntiemeticsAndAntinauseants.A04AA01_Ondansetron;

model Ondansetron
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 6.666666666666667e-06,
    adminDuration = 600,
    adminMass = 8 / 1000000,
    adminCount = 1,
    Vd = 0.16,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016666666666666666,
    Tlag = 10.200000000000001,
    Vdp = 0.061799999999999994,
    k12 = 8.638888888888889e-06,
    k21 = 8.638888888888889e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ondansetron</td></tr><tr><td>ATC code:</td><td>A04AA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>8</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>160</td><td>L</td></tr>
    <tr><td>clearance:</td><td>24</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ondansetron is a selective serotonin 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiotherapy, and surgery. It is approved and widely used internationally.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in healthy adult volunteers following single oral dose administration.</p><h4>References</h4><ol><li><p>Zhu, Y, et al., &amp; Zhu, J (2015). Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers. <i>Drug design, development and therapy</i> 9 4621–4629. DOI:<a href=\"https://doi.org/10.2147/DDDT.S86415\">10.2147/DDDT.S86415</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26316701/\">https://pubmed.ncbi.nlm.nih.gov/26316701</a></p></li><li><p>Fox-Geiman, MP, et al., &amp; Stiff, P (2001). Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. <i>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</i> 7(11) 596–603. DOI:<a href=\"https://doi.org/10.1053/bbmt.2001.v7.pm11760147\">10.1053/bbmt.2001.v7.pm11760147</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11760147/\">https://pubmed.ncbi.nlm.nih.gov/11760147</a></p></li><li><p>Zersen, KM, et al., &amp; Shropshire, SB (2024). Plasma Concentrations of Oral Ondansetron in Hospitalized Dogs Exhibiting Clinical Signs of Nausea. <i>Veterinary sciences</i> 11(3) –. DOI:<a href=\"https://doi.org/10.3390/vetsci11030112\">10.3390/vetsci11030112</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38535846/\">https://pubmed.ncbi.nlm.nih.gov/38535846</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A04AA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ondansetron;
